Stepping forward in the pharmacological treatment of advanced renal cell carcinoma – Royal Australasian College of Surgeons

On completion of this program, participants will be better able to:

1. recall the current clinical guideline recommendations for mRCC management
2. discuss the mechanisms of action, indications, contra-indications, side effect profiles and Pharmaceutical Benefits Scheme (PBS) listing of first- and second-line therapies for metastatic renal cell carcinoma (mRCC)
3. evaluate the evidence for efficacy and safety, as well as the health related quality of life (HRQoL) for first-line therapies both from clinical trials and real world data
4. manage patients with mRCC including therapy initiation, ongoing clinical monitoring, assessment of efficacy and management of side effects and disease progression